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ABSTRACT The purpose of this pilot study was to determine the feasibility of conducting a full study comparing the differential effects of pre-treatment with atracurium, pre­treatment with lidocaine, and pre-treatment with atracurium and lidocaine on the severity of fasciculations in patients who received succinylcholine. The research question under examination was: will there be any difference in the observed severity of fasciculation in subjects receiving succinylcholine who also receive one of three pharmacological regimens consisting of either lidocaine, atracurium, or lidocaine and atracurium in combination? Since the date that d-tubocuraine became commercially unavailable, no alternative pharmaceutical agent has been identified in the published literature as an optimal medication, either by dose or regimen, to prevent the occurrence or decrease the severity of fasciculations, following the administration of the depolarizing muscle relaxant succinylcholine. Muscle fasciculations have been associated with myalgia, as well as increases in intragastric, intracranial, and intraocular pressure. The bulk of investigation in this area, to date, has focused on the use of the non-depolarizing muscle relaxants rocuronium and atracurium. These muscle relaxants have been used alone and in combination with the local anesthetic, lidocaine, as a pretreatment prior to the administration of succinylcholine. All three of these medications (rocuronium, atracurium, and lidocaine) have demonstrated effectiveness at decreasing fasciculations when administered alone and in combination. No specific dosing schema, however, has been universally demonstrated to be most effective in decreasing or eliminating fasciculations in association with succinylcholine use. vii 
The study was a randomized, double blinded, quasi-experimental research design. The researcher approached subjects from the daily operating room schedule at a 600-bed Level I Trauma Center in the Southeastern United States who met all inclusion criteria and no exclusion criteria for participation. The population studied was limited to patients undergoing laparoscopic surgery, with an ASA physical status of I or II, between the ages of 18-50, with a BMI between 18-30. The measurement instrument selected to measure fasciculation was a four-point scale called the Observers Assessment of Fasciculation Scale. Results of this pilot study showed that 1.5mg/kg of lidocaine was able to prevent fasciculations in 75% of subjects, 0.05mg/kg of atracurium to prevent fasciculations in 40% of patients, and their combination to prevent fasciculation in 60% of subjects. However, all three groups were effective at limiting observed fasciculations to a score of 1 on the instrument utilized. It is recommended that this study should be replicated utilizing a larger population because the relative ease of subject access and the considerable degree of clinical significance found as a result of the conduction of the study. Further more, it appears that this pilot study allowed only for the possibility that smokers may be more likely to fasciculate than non-smokers, regardless of any of the pretreatment regimens used for this pilot study. This finding should be investigated in great depth in future studies. viii 
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CHAPTER I Introduction It is well documented that the administration of succinylcholine (SCh) causes muscle fasciculations, which may lead to untoward problems, including severe postoperative muscle soreness (Wong & Chung, 2000). As a result, it is acceptable standard anesthetic practice to aim to decrease the likelihood of fasciculations when administering SCh during the administration of general anesthesia. Historically, many methods for prevention of fasciculations have been employed. These have included pretreatment with any of the following medications: Dantrolene, calcium gluconate, lidocaine, phenytoin, ascorbic acid, magnesium sulfate, acetylsalicylic acid, non-steroidal anti-inflammatory agents, chlorpromazine, diazepam, midazolam, or subtherapuetic doses of nondepolarizing neuromuscular blockade, such as atracurium (0.05 mg/kg). In addition to all of these pharmacologic interventions, high doses of lidocaine (1.5-3 mg/kg) have been shown to be effective in reducing fasciculations and post-operative myalgias secondary to the use of SCh (Raman & San, 1997). All of these modalities have not, however, been consistently reliable in their ability to prevent fasciculation 
Purpose of the Study The purpose of this pilot study was to examine and compare the efficacy of pretreatment with lidocaine, atracurium, or lidocaine and atracurium in combination as they relate to the incidence and severity of fasciculation in subjects receiving succinylcholine. A second purpose was to determine the feasibility of conducting a full­scale research study to compare the differential effects of pretreatment with lidocaine, 
I 
atracurium, or lidocaine and atracurium in combination as they relate to the incidence and severity of fasciculation in subjects receiving succinylcholine. A third purpose was to identify correlations between demographic data and fasciculation in subjects who received lidocaine, atracurium, or lidocaine and atracurium in combination as they relate to the incidence and severity of fasciculation in subjects receiving succinylcholine. The research question asked: Will there be any difference in the observed severity of fasciculation in subjects receiving SCh who also receive one of three pharmacological regimens consisting of either lidocaine, atracurium, or lidocaine and atracurium in combination? 
Research Hypothesis and Physiological Framework The null hypothesis for this study states that there will be no difference in the observed severity of fasciculations in surgical patients who receive SCh who are pretreated with one of three pharmacological regimens consisting of either lidocaine, atracurium, or lidocaine and atracurium in combination. The framework that guided this research study was based on the currently accepted evidence that the neurotransmitter acetylcholine (ACh) acts on both the postjunctional cholinoceptors as well as the prejunctional cholinoceptors to mobilize ACh from reserves in prejunctional sites in quantity sufficient to keep up with the demand from stimulation (Bowman, 1980). Succinylcholine is the most commonly used depolarizing muscle relaxant in the United States. When administered, SCh binds to and activates the same receptors as does the neurotransmitter ACh. When ACh receptors are stimulated, rapid muscle relaxation or paralysis occurs by desynchronized depolarization of the muscle member (sarcolemmea), which results in disorganized muscle contractions, which are called 2 
fasciculations. These disorganized muscle contractions lead to a period of muscle relaxation called a refractory period. One way SCh differs from ACh is that the former is not metabolized by acetylchoinesterase in the synaptic cleft. Instead, SCh is hydrolyzed by cholinesterase in the plasma. Depending on the quantity and quality of an individual's plasma cholinesterase, SCh remains available to bind repeatedly with the ACh receptors (Lien & Savarese, 2000). The suppression of SCh-induced fasciculations results from the ability of nondepolarizing drugs, such as tubocurarine, to act on prejunctional receptors to prevent repetitive discharging of motor nerve terminals (Hartman, Fiamengo, & Riker, 1986). The potential benefits to the subjects of this study, and any subsequent full study, include a more comfortable recovery time void of additional post-operative discomfort from SCh-induced myalgias, prevention of muscle cell breakdown that leads to myoglobinuria that has been demonstrated to result in renal failure in some susceptible individuals, fewer returns to the emergency room for discomfort related to fasciculation, and the potential for a decreased need for post-operative pain medication secondary to cellular damage related to fasciculation. Preventing these sequale related to fasciculation could potentially allow subjects to return earlier to their preoperative baseline status. All future pat!ents who undergo surgery and receive SCh could be potential benefactors from the findings of this study. If this study demonstrates that lidocaine, atracurium, or a combination of both lidocaine and atracurium administered prior to SCh has a superior ability to diminish or prevent fasciculations, future surgical patients may experience fewer side effects of fasciculations related to SCh administration. 
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CHAPTER II Review of literature When rapid control of the airway is required, such as would be the case in patients with full stomachs, parturients, trauma victims, and individuals with existing active reflux disease, SCh is the fastest acting muscle relaxant used to facilitate endotracheal intubation. Currently, SCh is the only depolarizing muscle relaxant in use in the United States. Succinylcholine exerts its effects by minimizing the action of ACh on cholinergic receptors, resulting in protracted depolarization of the postjunctional membrane following administration of an intravenous dose of SCh. Ion channels in the myoneural membrane remain open for an extended period of time due to the slow hydrolysis of SCh. This delay of breakdown, and the elimination properties of SCh, prevent repolarization and so inhibit further muscular depolarization response despite succeeding release of ACh from the neuronal �nd plate (Stoelting, 1999). The phannocodynamics of SCh allow for rapid onset (30-60 seconds) and short duration of action of 3-5 minutes (Stoelting, 1999). Despite these desirable properties, SCh has several routine adverse effects that can limit its use. These include cardiac dysrythmias, hyperkalemia, myalgia, myoglobinuria, increased intragastric pressure, increased intraocular pressure, increased intracranial pressure, sustained skeletal muscle contractions or fasciculations (Stoelting, 1999), and elevation of serum creatine kinase and potassium (Cannon, 1994). The literature has reported the occurrence of fasciculations following SCh administration to • be associated with all of these undesirable effects. 
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Standaert (1994) defined fasciculations as the simultaneous contraction of the 
multitude of muscle cells in a single motor unit. Succinylcholine acts like A Ch to 
depolarize the prejunctional receptors in the neuromuscular junction, but differs from 
ACh in the fact that the depolarization caused by SCh is sustained. This characteristic is 
related to the chemical properties of SCh, which significantly slows its breakdown in VIVO. 
In a review article, Bowman (1980) described the classical view of neuromuscular 
transmission. He stated that nerve impulses cause the release of ACh from the terminal 
nerve endings. The released ACh then acts on the cholinergic receptors located on the 
motor end plate in the postjunctional membrane. It is at this final receptor that 
neurotransmitter coupling occurs, which leads to depolarization and muscle contraction. 
Other investigators have challenged this point of view over the years. In 1970, Blaber 
showed that ACh also works prejunctionally to mobilize additional transmitter reserves. 
He demonstrated this activity with decamethonium, a drug that acts similarly to ACh on 
the motor end plate. By using Tubocurarine, a nondepolarizing muscle relaxant, which is 
known to work on prejunctioninal receptors, Blaber (1970) was able to block the effects 
of decamethonium, thereby demonstrating prejunctional involvement. Kitamura, 
Yoshiya, Tashiro, and Negishi, in their 1981 study, injected 35 rabbits with neurotoxins 
that work specifically on prejunctional receptors. Their findings suggested the possible 
action of SCh on the prejunctional site. Therefore, the mechanism to suppress SCh­
induced fasciculation was postulated to be through the blockage of the prejunctioninal 
receptors. 
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The physiology of muscle fasciculations associated with the use of SCh is well understood. The basis of scientific understanding of SCh has been attributed to the effects of this agent on the prejunctional site, which, when stimulated, results in the individual asynchronous depolarization of muscle cells, causing generalized uncoordinated muscle contractions (Hartman, Fiamengo, Walter, & Riker, 1986). Muscle hyper-excitability from SCh can be reflected by myotonia and hyperkalemia, and this effect can be credited to up-regulation of ACh recept�rs (Haeseler et al., 2000). Haeseler et al. looked at the active metabolite of SCh, succinic acid, as a possible cause of fasciculations. Using human skeletal muscle sodium channels expressed in human embryonic kidney cells, these authors found that succinic acid had similar affects on voltage-dependent activation as does low calcium levels, which could lead to nerve and muscle cell excitability and spastic skeletal muscle contractions. Many authorities are investigating ways to prevent the occurrence of fasciculations after the administration of SCh with the intent of curtailing the occurrence of skeletal fasciculations which result from SCh administration (Cannon, 1994). Investigators have examined this phenomenon from a variety of angles and have utilized a multitude of different pharmacologic agents during their investigations for an optimal treatment to prevent fasciculations. These include benzodiazepines, nondepolarizing muscle relaxants (NDMR), and the local anesthetic, lidocaine. However, the current literature fails to support any one intervention as the best treatment. To date, the use of NDMR to prevent or decrease fasciculation remains the focus of most investigators as nondepolarizing muscle relaxants have been shown to most effectively decrease muscle fasciculations following the administration of SCh. 
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Erkola, Salmenpera, and Tammisto (1980) compared diazepam and tubocurarine ( dTc) 0.05mg/kg as a pretreatment to prevent fasciculations. Sixty-one subjects were randomly placed into one of three groups, a diazepam group, tubocurarine group, and a control group utilizing saline. The researchers found that dTc decreased the severity and frequency of fasciculations, where the diazepam failed to do so compared to the control group. They also measured potassium levels after SCh and found these measurements to be lower in the dTc group than in the diazepam group. In the 1990 issue of the British publication Anaesthesia, Mingus, Herlich, & Eisenkraft detailed their double-blinded, randomized study comparing two NDMRs with midazolam to determine which agent would best attenuate fasciculations among 80 female patients who underwent laproscopic surgery. Again, the subjects in the benzodiazepine group had a greater incidence of fasciculations than did the subjects in the NDMR groups. Another study with midazolam was carried out to see if the occurrence of fasciculations could be diminished with benzodiazepine pretreatment. In their 1993 study, Quentin, Fisher, & Matjasko found no significant decrease in the frequency of fasciculations when midazolam was administered, as compared to normal saline when administered to 69 female patients who underwent diagnostic laparoscopies or tubal ligations. In 1995, Stacey, Barclay, Asai, & Vaughan were unable to evidence a decrease in potassium levels in subjects who received intravenous magnesium before a depolarizing muscle relaxant dosage was administered. These authors did find in randomized groups, however, that fasciculations occurred less often when magnesium was administered prior 
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to rapid sequence intubation utilizing SCh to facilitate endotracheal intubation. The decrease in fasciculations was attributed to magnesium's ability to inhibit the release of A Ch and thereby diminish the occurrence of fasciculation. Multiple investigators have attempted to decrease SCh-induced fasciculations by administering either small doses of SCh or a NDMR as pretreatment (Osullivan, Williams, & Calvey, 1988; Koenig, 1992; Blanc, Vaillancourt, & Brisson, 1986; Harvey, Roland, Bailey, Tomlin, & Williams, 1998). The pretreatment doses of SCh and elapsed time prior to induction varied as follows: 10mg and 45seconds, O. l mg/kg and 60seconds, 0. l mg/kg and 60seconds, and 0.3mg/kg and 210 seconds. All studies, with the exception of one (Koenig, 1992), found SCh to be less effective in attenuating fasciculations when compared to NDMR. The group size varied respectively as follows: 15 subjects/group, 19/20 subjects per group, 16 subjects/group, and 20 subjects/group. Osullivan, Williams, & Calvery used _60 ASA Physical Status-I females ages 19-66 for elective plastic, ENT, and gynecological surgeries. Harvey, Roland Bailey, Tomlin, & Williams studied 101 ASA Physical Status I and II subjects ages 18-65 without regard to type of surgery. Koenig used 45 adult head trauma patients presenting to the emergency room who . required intubation and Blanc, Vaillancourt, & Brisson utilized children ages two-nine classified as meeting ASA Physical Status-I requirements. Interpretation of the results may differ since the doses and time frame before inductions also varied. Some of the nondepolarizing muscle relaxants that have been studied as a pre­. treatment to attenuate SCh-induced fasciculations include pancuronium, vecuronium, . atracurium, tubocurarine, rocuronium, cis-atracurium, and gallamine. There have been multiple documented studies comparing many types ofNDMR as possible treatments to 9 
prevent fasciculation. Researchers have attempted to discern optimal dosages of medications, as well as the ideal timing of their administration. To date, no conclusive findings have been published that identify the optimal treatment or specific agent for attenuating succinylcholine-induced fasiciculations. The traditional view regarding the pharmacodynamics of NDMR, such as tubocurarine on neuromuscular transmission, holds that such drugs work on the postjunctional receptors by blocking Ach; thereby preventing neuromuscular transmission (Wong & Chung, 2000). It is generally accepted that different NDMRs work on different parts of the neuromuscular junction. This belief supports the observations of why pretreatment with different NDMRs have different incidences of fasciculation. After completing their study, Osullivan, Williams, & Calvey (1988) suggested that a NDMR may modify fasciculations by inhibiting prejunctional depolarization leading to decreased rate of motor unit firing. Bowmans work in 1980 also suggested that NDMRs act on both presynaptic and postsynaptic receptors. All NDMRs have a different speed of onset, which is a characteristic of their individual chemical properties. Therefore, it is a logical reasoning that the speed of onset of a specific drug may affect how well the drug works to prevent fasciculations. In addition, the time interval between the administration of the NDMR and the administration of SCh influences the NDMRs ability to prevent fasciculations. Pinchak, Smith, Shepard, & Patterson conducted a study in1994 that compared the incidence of fasciculations when pancuronium 1 mg, atracurium 5mg, tubocurarine 3mg, and vecuroniumlmg were administered at different time intervals prior to SCh administration. A potential source of weakness in this pilot study was that the sample 10  
sizes among their different groups were not equal. However, the exact numbers of subjects in any one group was small, which limits how generalizable the findings are. Intervals of 0-1, 1-2, 2-3, 3-4, and 4-5 minutes were compared. Waiting time response curves were calculated from the gathered data. Confidence intervals were set at 95%. Results demonstrated the incidence of observed fasciculations decreased with increasing waiting time for each NDMR tested. The probability of preventing fasciculation 80-90% of the time occurred when tubocurarine was given either two minutes and 46 seconds or three minutes and two seconds before SCh administration, and when atracurium was . given two minutes and 16 seconds or three minutes and 24 seconds prior to the administration of SCh. These results could be explained based in part on the drug's potency. In a 1992 study by Law Min, Bekavac, Glavinovic, Donati, & Bevan, frog muscle in vitro was utilized to show that the speed of onset of the NDMRs under investigation was inversely proportional to each drugs potency. These authors related their findings to the accepted belief that less repetitive binding occurs on A Ch receptors in association with less potent NDMR. The concept of diminished binding characteristic of less potent NDMRs is now widely accepted. Contrasting these findings, Motamed, Choquette & Donati, (1997) used equipotent doses of rocuronium in 42 pa�ients and administered the doses at 1.5 and three minutes respectively. However, even though the three-minute group had fewer fasciculations, the difference was statistically insignificant. The current literature regarding defasciculating doses ofNDMRs appears to be focused on the use of rocuronium and atracurium. Some of the many authors that have yielded significant contributions to the current body of knowledge regarding the use of 
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rocuronium and atracurium include: Tsui, Reid, Gupta, Kearney, Mayson, & Finucane, (1998); Demers-Pelletier, Drolet, Girard, & Donatie, (1997); Martin, Carrier, Pirlet, Claprood, & Tetrault, (1998); Pinchak, Smith, Shepard, & Patterson, (1994); Raman & San, (1997); Harvey, Roland, Bailey, Tomlin, & Williams (1998); Kim, Cho, Lee, Lim, Chang, & Yoon ( 1999). Those who have explored this subject have not universally agreed upon the dosage ofrocuronium that works best as a defasciculator. Neither have they been able to reach a consensus regarding the optimal time from administration of NDMR and SCh to fasciculation, nor the dose of SCh that is associated with the greatest degree of fasciculation. Dosages of rocuronium that have been evaluated in studies investigating the inhibition of fasciculation include 0.03mg/kg 0.05mg/kg, 0.06mg/kg, and 0. l mg/kg. Time elapsed between the defasciculating doses ofNDMR and the administration of SCh also have varied by 2.5 minutes (with a range of l .5min., 3min., and 4minutes). Dosage of SCh has been fairly standard and consistent at 1 .5mg and 2mg. Demers-Pelletier, Drolet, Girard, & Donati (1 997) and Motamed, Choquette, & Donati, (1997) both used similar sample sizes and looked at 0.05mg/kg of rocuronium with a 1 .5-minute interval. Results of these studies demonstrated that 52% and 70% of subjects respectively did not fasciculate when pre-treated with 0.05mg/kg of rocuronium. Motamed et al., examined rocuronium administered at 0.05mg/kg followed at three minutes by SCh and found 90% of the subjects did not fasciculate. Since different scales were used to judge the intensity of the fasciculations that occurred, however, it was not possible to make an adequate comparison of these findings between these studies. Martin, Carrier, Pirlet, Claprood, & Tetrault (1998) and Mencke, Schreiber, Becker, Bolte, & Fuchs-Buder (2002) used rocuronium at a dose of 0.06mg/kg and 1 2  
allowed a four-minute interval to elapse prior to SCh administration. Both of these studies revealed 85% and 80% of 20 and 40 subjects respectively did not exhibit evidence of fasciculations. A defasciculating dose of 0.6mg/kg of rocuronium is equal to 10% of the intubation dosage of rocuronium when the intubation dose is twice the published effective dose of 95% of the population. In contrast, a study published in the October 2002 issue of the Journal of the American Association of Nurse Anesthetists, by Spence, Domen-Herbert, Boulette, Olson and Maye found 0.03mg/kg of rocuronium to be effective in preventing fasciculations in 70% of subjects with a three-minute interval between the time of administration of the pretreatment (atracurium) and administration of SCh. Disagreement in the literature, from this author's review, appears to be the only consistency in regard to this subject matter. According to Stoelting ( 1999); the lack of potency of rocuronium is considered to play a key factor in its rapid onset and effectiveness as a defasciculator. These observations result from a greater number of molecules being available in the neuromuscular junctions. Eighty-five percent of the subjects studied by Martin, Carrier, Pirlet, Claprood, & Tetrault (1998) who received 0.06mg/kg (10% of intubating dose) of rocuronium did not show evidence of fasciculations. In the same study, the authors reported using 0.02mg/kg (<10% of the intubating dose) of atracurium, 0.0 lmg/kg ( 10% of the intubating dose) of vecuronium, 0.06mg/kg {>10% of the intubating dose) of mivacurium, and 0.05mg/kg (10% of the intubating dose) of tubocurarine for comparison. All of the NDMRs reduced fasciculations, but to a lesser extent than rocuronium. A four­minute time interval between NDMR administration and the administration ofSCh was utilized. Given the larger dose of rocuronium used, and the longer time interval before the 
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administration of SCh, it is surprising that a greater percentage of subjects failed to show evidence of fasciculations than was observed. In a study performed by Mencke, Schreiber, Becker, Bolte, & Fuchs-Buder in 2002, 80% of the subjects who received rocuronium had a reduction in severity and incidence of fasciculations as opposed to 2.5% in the control group. The authors did not delineate an ordinal breakdown of fasciculation severity as other authors had done. The ability for rocuronium 0.05mg/kg and vecuronium 0.007mg/kg (a smaller dose then in other studies) to defasciculate were compared after a time interval of three minutes in two equal sized samples. Again, rocuronium was superior with 85% of subjects inhibited from fasciculating in contrast to 50% of the vecuronium group subjects experiencin� fasciculation (Kim, Cho, Lee, Lim, Chang, & Yoon, 1999). In another study with smaller subject groups comparing .rocuronium with atracurium (an intermediate acting NDMR), higher doses of both drugs were used. This study utilized O. l mg/kg of both drugs with, 1 .5-minute time intervals between their administration and the administration of SCh. This study found rocuronium to be four times more effective at reducing fasciculations (78% versus 21  % reduction) in comparison to atracurium (Tsui, Reid, Gupta, Kearney, Mayson, & Finucane, 1998). Atracurium, an intermediate acting NDMR, has been found to be an effective treatment to reduce fasciculations when SCh is administered. Atracurium works by blocking both the presynaptic and postsynaptic receptors of the neuromuscular junction (Hughes & Pa�e, 1983). In a study comparing atracurium to tubocurarine, atracurium at a dose of0.025mg/kg was found to be effective at reducing fasciculation, but less so than 0.05 mg/kg of tubocurarine (Sosis, Broad, Larijani, & Marr, 1987). More recent studies 
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have used higher doses of atracurium, (0.05mg/kg) in an attempt to prevent fasciculation. In 1996, Hochhalter, compared 0.05mg/kg of atracurium with a control group receiving normal saline. The time interval between administration and fasciculation was three minutes. Hochhalter found atracurium to be effective with 73% of the subjects failing to exhibit any measured fasciculations (n=24). Raman & San (1997) compared subjects receiving 0.05 mg/kg of atracurium in combination with 1.5 mg/kg of lidocaine, 0.05mg/kg of atracurium without lidocaine, l .5mg/kg of lidocaine without atracurium, and a control group receiving none of these drugs. Study results indicated atracurium in combination with lidocaine was more effective than atracurium alone. Seventy percent of subjects receiving atracurium in combination with lidocaine showed no signs of fasciculation, while " only 60% of the subjects who received atracurium demonstrated absence of fasciculation. All subjects received their pretreatment three minutes before SCh was administered. Higher doses of atracurium were utilized in a study by Tsui, Reid, Gupta, Kearney, Mayson, & Finucane (1998). These authors used a dose of atracurium 0.lmg/kg along with a shorter (1.5-minute) interval between atracurium administration and the subsequent SCh administration. In this study, 79% of subjects failed to have fasciculation inhibited. The difference between the ti.me intervals of 1 .5 minutes versu� 3 minutes, made more difference than the drug dosage, and was most likely responsible for the greater observed difference. It should be noted that in both studies by Hochhalter (1996) and Raman & San (1997), using 0.05mg/kg of atracurium with a three minute interval of elapsed time prior to SCh proved to be effective in reducing fasciculations. Martin, Carrier, Pirlet, Claprood, & Tetrault (1998) utilized a four minute waiting period 
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between the administration of atracurium 0.02mg/kg, rocuronium 0.06mg/ kg, 0.01 
mg/kg, or mivacurium 0.02mg/kg and SCh administration. Sixty-five percent of the 
subjects receiving atracurium did not fasciculate. This is in contrast to fasciculation 
inhibition of 85% in the rocuronium group. Although the four-minute time interval used 
by Martin et al. should have been long enough for both of these NDMRs to adequately 
block the prejunctional receptors, the study findings did not support this supposition. This 
author postulates that perhaps the lower dose of atracurium (0.02mg/kg ) that Martin et 
·al. used in their study accounted for the difference in the incidence of fasciculations in 
these study subjects. 
The efficacy of the local anesthetic lidocaine to reduce fasciculations and 
associated myalgias has been compared to the efficacy ofNDMRs to reduce the same. 
Lidocaine is thought to be effective because it has membrane-stabilizing effects 
(Winkinski, Usubiaga, Usubiaga, & Wikinski, 1965). Naguib, Farag, & Magbagbeola 
(1988) observed fasciculations in 10 subjects given lmg/kg of lidocaine. The intensity of 
fasciculations in the study' s subjects was comparable to those observed in the control 
group. Study results, therefore, did not support the idea that lidocaine would be effective 
in preventing fasciculation in association with SCh administration. 
Lidocaine has also been compared with rocuronium in the search for the most 
effective and least problematic agent to utilize for fasciculation inhibition. Seventy-nine 
percent of subjects receiving 1.5 mg/kg of lidocaine, compared to 29% of subjects 
receiving 0.03mg/kg of rocuronium, showed signs of fasciculations in results reported by 
Spence, Domen-Herbert, Boulette, Olson, Vacchiano, & Maye in 2002. 
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Conversely, in their 1997 study of fasciculations following SCh administration, Raman and San observed that 85% of subjects in their lidocaine group showed signs of fasciculation. In their study Raman and San also examined the administration of atracurium and a combination of lidocaine and atracurium and found that the combination decreased the incidence of fasciculations more so then either drug administered alone. Sixty percent of the subjects in the atracurium group did not fasciculate when SCh was subsequently administered. All groups contained 20 subjects. A third study using a large sample of 395 randomly assigned subjects by Melnick, Chalasani, Lim Uy, Phitayakom, Mallett, & Rudy compared l .5mg/kg of lidocaine, 0.06mg/kg tubocurarine, or a combination of both l .5mg/kg of lidocaine and 0.06mg/kg oftubocurarine to a control group who only received normal saline (1987). The subjects in the tubocurarine groups had a lower incidence of fasciculations when compared the subje�ts in both the saline and lidocaine groups. Lidocaine was not found to decrease fasciculation when compared to the control group in this study. The com�ination of lidocaine with tubocurarine, however, was found to decrease both the incidence and severity of fasciculations greater than any agent either alone or in combination. Nondepolarizing muscle relaxants attenuate fasciculation by their action on the prejunctional cholinergic receptors. To date, the bulk of research on the attenuation of fasciculations with SCh use has focused on the use of atracurium and rocuronium prior to depolarizing muscle relaxant administration. No consensus, however, is to be found in the body of literature regarding the optimal dosages or time jnterval between the NDMR pretreatment, the most effective dose ofNDMR, or the most effective dose of SCh administered. Of the studies examined for this review it was found that (1) The dosages 17  
ofNDMR that seemed to be most efficacious for diminishing fasciculations related to SCh administration were those doses which were approximately 10% of the intubating dose of the same agent. For atracurium the dosage would be 0.05mg/kg, whereas for rocuronium the dosage would be 0.06mg/kg. (2) The most efficacious time interval, which appeared to be most effective in preventing fasciculation, was at least three minutes between the administration of the nondepolarizing dose and the intubating dose of SCh. (3) Lidocaine given alone, in the published literature, has been shown to be ineffective at decreasing the incidence of fasciculations in association with SCh administration. Flaws in study design and sampling where lidocaine has been investigated, however, diminish the generalizability and, thus the value of these findings. In combination with nondepolarizing muscle relaxants, lidocaine has been shown by some researchers to enhance the effects ofNDMRs ability to attenuate fasciculation compared to either agent given alone. Therefore, this pilot study served to determine whether or not it was feasible to seek to determine the most effective utilization of atracurium, atracurium and lidocaine, and lidocaine for the inhibition of muscular fasciculation in patient's receiving SCh, as measured by the Observers Assessment ofFasciculation Scale. In summation, it is the currently accepted scientific belief that prejunctional cholinergic receptors, when stimulated by SChs, are responsible for causing muscular fasciculations secondary to propagated neuronal impulses. Pretreatment with higher dose nondepolarizing muscle relaxants administered at longer time intervals prior to SCh administration has been shown to be the most effective treatment in preventing 
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fasciculations. The practice of utilizing higher doses ofNDMRs and waiting longer intervals between the administration of the NDMR and SCh, while effective in decreasing fasciculations, has inherent risks to patients. These risks include higher potential of passive gastric reflux leading to aspiration, hypoxia, and hemodynamic instability related to the induction and maintenance of general anesthesia in the absence of any appreciable sympathetic nervous system stimulation. Continued investigation for the most effective, but least problematic agent, or combination of agents, to prevent fasciculation is therefore warranted and necessary. 19  
Introduction 
CHAPTER III Methodology The primary purpose of this study was to examine and compare the efficacy of pretreatment with lidocaine, atracurium, or lidocaine and atracurium in combination as they relate to the incidence and severity of fasciculation in subjects receiving succinylcholine. A second purpose was to determine the feasibility of conducting a full study to compare the differential effects of pretreatment with lidocaine, atracurium, or lidocaine and atracurium in combination as they relate to the incidence and severity of fasciculation in subjects receiving succinylcholine. The third purpose of this study was to identify correlations between demographic data and fasciculation in subjects who lidocaine, atracurium, or lidocaine and atracurium in combination as they relate to the incidence and severity of fasciculation in subjects receiving succinylcholine, such as the relationship between smoking and the occurrence of fasciculations, as well as differences between gender and fasciculations that could hold clinical significance. The Observers Assessment of Fasciculation Scale (OAFS) was the instrument used to measure the severity of fasciculations. The OAFS is a four-point ordinal tool that ranks observed muscular fasciculations on a scale of 0-3 based on their occurrence and severity. The first section of this chapter explores the research design of this pilot study instrument. The remainder of this chapter will present the research design as it relates to subject sample and setting, operational and theoretical definitions, assumptions, inclusion and exclusion criteria, study limitations, instrumentation, data analysis, study protocol, and instrumentation, which will be utilized as the foundation of this clinical investigation. 
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Protection of human subject's rights considerations will be presented at the conclusion of this chapter. 
Research Design Subjects recruited for participation in this study were identified and selected by means of convenience sampling of all patients who are listed on the daily surgical schedule at the research site. All subjects studied met the inclusion criteria and were void of any exclusion criteria. This study was a prospective, double-blinded, randomized study of 15 ASA Physical Status I and II subjects. Subjects were randomly assigned to one of three groups. Group one was pre­treated with atracurium 0.05mg/kg IV prior to administration of l .5mg/kg IV of SCh. Group two received l .5mg/kg IV of lidocaine prior to l .5mg/kg of SCh. Group three received both pretreatment agents at the above-indicated doses. No control group was utilized, since fasciculations are a normal expectation with SCh administration and withholding intervention was considered to be an unethical practice by this author. The specific details of the protocol are detailed later in this chapter. Pretreatment medications in all three groups were administered to subjects using a double-blind format. The surgery pharmacy randomly assigned subjects to one of the three study groups by means of computerized random selection. Syringes of study medications were labeled with numbers (from 1- 15) by the pharmacy staff for each subject enrolled in the study. The only study participants who knew which patient received which study medication prior to the completion of the study was the operating room pharmacy staff. The pharmacy staff disclosed this information when all data had been collected and when the study was completed and the project was closed since no 
22 
problem arose that required the investigator's or other providers ' knowledge of this 
information prior to the study' s completion. Every syringe contained the same volume 
amount, however, the content of the syringe varied depending on which investigational 
group the subject is assigned. Dosages of all medications were calculated based on body 
weight (in kilograms) by the pharmacy prior to anesthetic administration. At the end of 
the study, the drugs were identified to conclude whether there was a significant difference 
between the pre-treatment groups with respect to comparison of o:ne another. One 
independent observer had to be utilized to judge fasciculations by the application of the 
OAFS. These data were to be analyzed after the completion of the study by the statistical 
computer program SPSS. 
All subjectswere assigned a number once enrolled in the study. Subjects were 
sequentially numbered 1 - f5 .  A demographic data sheet served as the master subject list 
and was maintained on all subjects who agree to participate in the study and who had 
signed the informed consent. This data sheet can be found in Appendix B and contained 
the following information: 
1 .  Name 
2. Phone Number (Contact information was collected because a secondary 
researcher was following up on the patient for a separate study looking at 
postoperative myalgia.) 
3 . Subject number ( 1 - 1 00) 
4. Physical Status classification 
5 .  Weight in Kg 
6. Height in centimeters · 23 
7. Gender 8. Smoking history 9. Pre-operative narcotic and NASID use (dose and duration) 10. Post-operative narcotic and NASID use ( dose and duration) Subjects were recruited by convince sampling. All individuals appearing on the daily operating room schedule who met study criteria had the opportunity to participate in this study. Subjects classified by the American Society of Anesthesiologists physical status classification I (ASA-I), or physical status classification II (ASA-II), who were between the ages of 18-50, and who were scheduled for elective outpatient laproscopic surgery under general endotracheal anesthesia were approached to determine eligibility to participate in the study. Those subjects identified by the investigator as meeting inclusion and exclusion criteria were asked to participate. The entire investigation took place in the surgical suites of a Level I adult and pediatric trauma center in the Southeast United States. 
Operational and Theoretical Definitions 1 .  Nondepolarizing Muscle Relaxant (NDMR}- Are neuromuscular relaxing agents that antagonize the neurotransmitter acetylcholine from reaching the acetylcholine receptors, preventing depolarization of skeletal muscle cells and muscle contraction. 2. American Society of Anesthesiologists (ASA}- The American Society of Anesthesiologists is an educational, research and scientific association of physicians organized to raise and maintain the standards of the medical practice of anesthesiology and improve the care of the patient. 
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3. ASA physical status I and II- Describes the physical status of a patient at the time of surgery. See Appendix B for specific definitions. 4. Defasciculation- The prevention of simultaneous contraction of skeletal muscle. 5. Fasciculations- Fasciculations are the simultaneous contraction of the multitude of muscle cells in a single motor unit (Standaert, 1994). These can be observed in all skeletal muscles in the human body. Skeletal fasciculation are most easily observed in the fingers, eyes, and limbs. 6. Endotracheal Anesthesia- General anesthesia that is delivered to the lungs through the trachea via an endotracheal tube. 7. Endotracheal Tube- A large catheter that is inserted through the nose or mouth, into the trachea, by which oxygen and volatile anesthetics are delivered. 8. Laparoscopic Surgery- Intra-abdominal surgery performed through small incisions with the use of laparoscopic instruments. These are surgical instruments that include a camera which transmits the image from inside the abdominal cavity that the surgeon uses to guide the surgical procedure. 9. Neuromuscular Junction- The area between the ends of myelinated nerve fibers and skeletal muscle. 10. Outpatient- A non-hospi�alized patient who receives same day medical treatment. 
Assumptions The basic assumptions made regarding this study were as follows: 1 .  Although the validity and reliability of the OAFS is essentially unproven, for the purpose of the current study, it was assumed that the OAFS was a reliable, predicative, and accurate tool for measuring fasciculations. 25 
2. Observed fasciculations by the independent observer was consistent for all subjects. 3. The population sample would be random. 
Inclusion Criteria 1. 18-50 years of age 2. Subjects requiring elective outpatient laproscopic surgery under general endotracheal anesthesia 3. Body Mass Index (BMI) between 18-30 4. ASA Physical Status I or II 5. Ambulatory patients only 
Exclusion Criteria 1. Those patients not meeting the inclusion criteria as detailed. 2. Allergy to study drugs (lidocaine or atracurium). 3. Subjects with co-existing disease states that could necessitate a diversion :from the planned anesthetic. 4. Subjects who are known or suspected to be pregnant. 5. Subjects who are non-ambulatory, bed-ridden, and/or wheelchair bound. 6. Any subject who does not have access to a telephone, thus preventing post-operative follow-up contact. 7. Subjects who receive narcotic reversals. 8. Refusal to participate in the study. 9. Subjects having any condition that would be contraindicated by the administration of any drug or procedure outlined in this study. 26 
10. Subject or family history of malignant hyperthermia. 
11. Subjects with known pseudocholinesterase disorder. 
12. Any subjects not able to give full voluntary and informed consent. 
Study Limitations 
The following conditions limit the conclusions that were drawn upon completion 
of this study: 
1. The review of literature may not be wholly reflective of reality . 
2. The individual subject variability in response to the prescribed anesthetic 
regimen. 
3 .  The possibility exists that multiple sources of error surrounding measurements 
of subject's fasciculation may skew the results. In the current study, the 
sources of measurement error had been minimized by the use of a single 
observer for the measurement of fasciculation, and a measurement tool that 
has been used by other researchers measuring fasciculation. 
4. The small population to be studied may not be large enough to make 
generalizations to larger population regarding the use of lidocaine alone, 
lidocaine with atracurium or atracurium alone and their role in preventing 
fasciculations. 
5 .  No control group is being studied for treatment comparison. 
6. The OAFS scale being utilized to measure fasciculations has not undergone 
extensive psychometric testing for validity or reliability. 
7. The influence of the amount and type of additional medications prescribed by 
the subject's surgeon during the pre-operative period. 27 
8. The amount and type of medication currently be utilized by the subject at the time of surgery. 
Data Analysis Comparison of the mean scores of the three study groups would traditionally have been performed by analysis of variance (ANOV A) utilizing parametric testing. However, this statistical application would have required a specific distribution of the mean and variance. Testing of the OAFS lies within a gray area and, as such, a distribution could not be assumed. Therefore, a nonparametric one-way ANOV A with post-hoc analysis was employed. Specifically, the Kruskal-Wallis, a test for two or more independent samples, and the Bonferroni test utilizing a significance level of p<=0.05 was emplored. The Kruskal-Wallis test calculates results based on the sums of the ranks of the combined groups in the OAFS. For example, the scores for each variable (0,1 ,2,3) were ranked, and the mean ranks for the variables were compared. If a significant difference had been found (p<=0.05), a post-hoc analysis utilizing the Bonferroni method would have been employed to identify where the difference would have laid. Depending on the gender make-up of the study population, a backwards regression test may have been used to analyze any relationships between gender and fasciculations, so as to identify which variable influenced the dependent variable the most. Because this method is more sensitive in small comparisons, it was to be utilized in this study. 
Protocol 1 .  After informed consent is obtained by one of the investigators, the subject will be transported to the operating room and positioned on the operating table appropriately for the surgical procedure to be performed. 
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2.  Standard monitoring will be in utilized (Appendix C). 3 .  Subject will be pre-oxygenated with 100% inspired oxygen for two minutes or five-vital capacity breathes. 4. The experimental pretreatment drug will be given with fentanyl 1 .5 mcg/kg. This dose of fentanyl is given to blunt stimulation from laryngoscopy and has not been demonstrated to affect myalgias in previous investigations. 5 .  Five minutes after the administration of the pretreatment drug an appropriate induction dose of propofol (2-2.5 mg/kg IV) will be given for the induction of general anesthesia. 6. After the induction dose of propofol is administered, and the subject loses their lid reflex, l .5mg/kg of SCh will be administered intravenously. The subject will be observed· for evidence of fasciculations. The fasciculation observer will be the same for. all subjects, and this individual who is trained and qualified as a research assistant, but is not one of the researchers will classify the severity of any witnessed fasciculation based on the 0-3 Observers Assessment of Fasciculation Scale (OAFS), (Appendix A) . 7. After complete muscle relaxation is verified by 0/4 twitches following ulnar nerve stimulation via cutaneous electrodes, tracheal intubation will be performed and endotracheal tube placement will be verified by standard methods. 8 .  Anesthesia will be maintained with oxygen, and air or  nitrous oxide, and by titrating sevoflurane 0.6%-5% to the individuals subject's homodynamic stability and necessary surgical level of anesthesia corresponding to the degree of surgical 29 
intervention required. The Bispectral Index (BIS®) monitor will be utilized as an adjunctive monitor to help assess the patient's level of anesthetic depth. 9. If the subject's blood pressure and heart rate fluctuates (increases or decreases) greater then 20% of their base line levels (Appendix D), then vasodilators, vasopressors, inotropes, or chronotropes will be administered as appropriate for the situation. If the subject fails to respond, they will be eliminated from this study, their data will not be utilized for analysis, and all further appropriate treatment necessary for the situation will be instituted. 10. The following drugs will be administered as their need arises: narcotics (fentanyl 2-10 mcg/kg), nondepolarizing muscle relaxants, antiemetics, steroids, antibiotics, vasoactive drugs, and muscle relaxant reversals. These medications are not part of the study protocol, but are routinely employed in the anesthetized patient. (See Appendix H for this study's formulary, doses and adverse effects of drugs). 1 1 .  After completion of the surgery, anesthesia will be discontinued. The subject will administered 100% oxygen, and will be extubated when extubation criteria are met (Appendix E). Following extubation, the subject will be taken to the post­anesthesia recovery room. 
Instrumentation The Observers Asses�ment of Fasciculation Scale (OAFS) was the tool used to gauge fasciculations in study subjects following SCh administration. The OAFS is a four-point ordinal scale that measures the severity of fasciculations from zero to three, where [O] indicates no fasciculations observed, [1 ] indicates mild fasciculations observed, [2] indicates moderate fasciculations observed, [3] indicates severe, vigorous 
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fasciculations observed (see Appendix A). Although the OAFS has been used in several previous studies of similar nature and scope as the current one, this scale has no proven validity or reliability. However, a version of this tool has been widely used by numerous authors to accurately measure fasciculation after SCh administration in studies of similar scope and intent as the current one (Harvey, Roland, Bailey, Tomlin, & Williams, 1998; Sosis, Broad, Larijani, & Marr, 1987; Joshi, Hailey, Cross, Thompson-Bell, & Whitten, 1999; Marr & Sosis, 1989). These authors have published their results in a vat:iety of respected and refereed scientific medical journals including: The Journal of the American 
Association of Nurse Anesthetists, Anesthesia and Analgesia, and The Journal of Clinical 
Anesthesia. Consequently, since no better or alternate tool existed which had a proven higher index of validity or reliability, this author chose to utilize this specific tool (the OAFS) in the study. The goal of using this tool was to measure the occurrence and severity of fasciculation following SCh administration subsequent to the administration of lidocaine, atracurium, or lidocaine and atracurium in combination. Since it was important to maintain consistency and provide reliable measurement during subject fasciculation, observer consistency was to be maintained by utilizing the same individual to judge and record the occurrence of fasciculations of all subjects using the OAFS on data collection sheet (see appendix F). 
Protection of Human Subjects All guidelines of the University of Tennessee Medical Center and The University of Tennessee-Knoxville Institutional Review Boards were adhered to in order to make certain that consideration and safety for subjects were met. No data collection occurred until approval was obtained from the Institutional Review Board (IRB) of the University 
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of Tennessee Medical Center and the University of Tennessee, Knoxville. As per requirement of the clinical site IRB, no identifying information was placed on the master subject data collection list, thus serving to protect and maintain subject anonymity. The master subject list and completed survey instruments remained under lock and key by the principle investigator (IRB approval, Appendix, J). Each subject was read a script that outlines the conditions of consent to participate. Informed consent was indicated by the subject's signed, witnessed agreement to randomly receive one of the three medication protocols and agreement to allow the observation of fasciculation to be measured and recorded on the OAFS by the independent observer. The use of this tool was approved by the IRB of both University of Tennessee Medical Center and the University of Tennessee, Knoxville. Subjects were made aware that they could withdraw from this study at any time without jeopardizing their care. The potential risk to subjects was minimal, if any. There were no additional identified or postulated physical, psychological, social, legal, or other risks to the subjects participating in this study when compared to nonparticipating patients undergoing routinely accepted anesthesia care for similar procedures. No drug or procedure included for use in this study was beyond the accepted scope of the current accepted anesthesia standard of care. In similar fashion, no drugs or procedures were utilized in any manner in this study that were not within the realm of accepted anesthesia practice. The only conceivable increased risk identified by the researchers for subjects enrolled in this study was that a subject might potentially be able to identify some portion of their data if contained in published studies. Given that all information for the current study was analyzed and reported as group data, the potential risk to any individual subject is 
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extremely small. Even so, the type of data captured in this study was not of a nature that should cause public embarrassment if revealed. Therefore the risk of injury had been estimated to be no greater than that encountered in normal everyday anesthesia practice. This was underscored by the fact that all medications used during this investigation were approved by the Federal Drug Administration for use in anesthesia for the purpose intended. No published data from this study will contain information that could be used to link any subject to the study results. All original materials and data will be maintained by the principal investigator for a period of five years following completion of the study, and will then be destroyed. The data obtained through the conduction of this study may be maintained in a database by the investigator and these data may be utilized by the same investigator in conjunction with future study, research, and publication. Prior to the conclusion of data collection, no subjects were identified by any method other than by sequential numbering on the demographic data sheet, ,and it never became necessary for the safety of the subject to reveal the blinded information. If such an instance had occurred (i.e. anaphylaxis or hemodynamic instability), the subject would have been removed from the study and the double-blinded protocol medication would have been revealed so as to have provided the most appropriate and prompt intervention as possible. Since all drugs and patient care interventions were routinely utilized and administered in the methods and manners for which they were approved, there was less than minimal potential for subject injury in relation to subject participation in this study. To date, there were no proven therapeutic alternatives. Many studies have been - . undertaken to examine this concept. However, these study results have been inconclusive in yielding definitive results. 33 
This study was designed to protect subject confidentiality at all phases of investigation. All demographic data sheets and master subject lists were under the direct supervision and control of the investigator for the duration of the study. Following the completion of the study, all data was placed in the anesthesia department in a locked file cabinet and will be kept for a period of 5 years. After such time ( or before if approved), original data will be destroyed via a paper shredder. The potential benefits to the subjects of this study, and any subsequent full study, include a more comfortable recovery time with less additional post-operative discomfort from SCh-induced myalgias, and a lower likelihood of muscle cell breakdown that could lead to myoglobinuria, which has been demonstrated to result in renal failure in some susceptible individuals. There may be fewer returns to the emergency room for discomfort related to fasciculation, and the potential for a decreased need for post­operative pain medication secondary to cellular damage related to fasciculation. The prevention of these sequale related to fasciculation could potentially allow subjects to return earlier to their preoperative baseline status. All future patients who undergo surgery and receive SCh could be potential benefactors from the findings of this pilot study. If this pilot study demonstrates that lidocaine, atracurium, or a combination of both lidocaine and atracurium administered prior to SCh has superior ability to diminish or prevent fasciculations, future surgical patients may experience fewer side effects of fasciculations related to SCh administration. The results obtained through this study have the potential to improve patient satisfaction. The most significant anticipated risk was that the pretreatment intervention 
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may have helped to prevent or diminish postoperative myalgias. Therefore, it was estimated that this study could ultimately benefit future patients tremendously by lowering the negative side effects of SCh, which were reviewed in Chapter II. Participants in this study did not receive payment or other inducement, in any form, for their participation. There was no additional cost to the facility for the conduction of the study or the participation of any subject. Participants in this study had no additional financial obligations as a result of participation. There were no additional costs to the research facility. There were no identified financial conflicts of interest. Prior to the conclusion of data collection, subjects were not identified by any method other than by sequential numbering on the demographic data sheet and it never become necessary, for the safety of the subject, to identify them prior to study completion. If such an instance had occurred (i.e. anaphylaxis or hemodynamic instability), they would have been removed from the study, and the double-blinded protocol medication would have be revealed so as to provide the most appropriate and prompt intervention as possible. Since all drugs and patient care interventions used are routinely utilized and administered in methods and manners for which they are approved, there was less than minimal potential for subject injury in relation to subject participation in this study. 35 
CHAPTER IV Results Chapter IV presents the results of the data analyses of the research question under investigation. The primary purpose of this study was to examine and compare the efficacy of pretreatment with lidocaine, atracurium, or lidocaine and atracurium in combination as they relate to the incidence and severity of fasciculation in subjects receiving succinylcholine. The second purpose was to determine the feasibility of conducting a full study to compare the differential effects of pretreatment with lidocaine, atracurium, or lidocaine and atracurium in combination as they relate to the incidence and severity of fasciculation in subjects receiving succinylcholine. A third purpose was to identify correlations between demographic data and fasciculation in subjects who received lidocaine, atracurium, or lidocaine and atracurium in combination as they relate to the incidence and severity of fasciculation in subjects receiving succinylcholine, such as the relationship between smoking and the occurrence of fasciculations, as well as differences between gender and fasciculations that could hold clinical significance. These purposes were guided by the following research questions: Will there be any difference in the observed severity of fasciculation in subjects receiving SCh who also receive one of three pharmacological regimens consisting of either lidocaine, atracurium, or lidocaine and atracurium in combination? The null hypothesis for this study stated that there would be no difference in the observed severity of fasciculations in surgical patients who receive SCh who are pretreated with one of three pharmacological regimens consisting of lidocaine, atracurium, or lidocaine and atracurium in combination? The data obtained as a result of the implementation of this investigation were gathered by the 
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utilization of the Observers Assessment of Fasciculation Scale (OAFS) as discussed in Chapter III. Subsequent to obtaining IRB approval from The University of Tennessee, Knoxville and The University of Tennessee Medical Center at Knoxville, the OAFS was implemented following subject consent to identify answers to the research question. The research study was initiated in June 2003, and data collection was completed in August 2003. Although the data set for this pilot study contained an inadequate number of subjects to allow for generalizations of statistical significance (n=14), several interesting observations were noted that hold clinical significance, and will be discussed in Chapter V. Fifteen subjects, who met the inclusion criteria, were approached for participation in this study. After an explanation of the study by the investigator, informed consent (Appendix G) was obtained from the subjects. The established and approved protocol was followed without deviation as detailed in the IRB application (Appendix H) . Of the 1 5  subjects who gave informed consent, one subject was excluded from data analyses because of intraoperative changes in surgical procedure that necessitated removal from study inclusion, leaving 14 subjects for statistical analysis. Five subjects were randomly assigned to each of the 3 study groups, with 5 subjects included in the atracurium group, 4 subjects assigned to the lidocaine group, and 5 subjects assigned to the atracurium/lidocaine group. Data analysis was calculated with the statistical software program Statistical Package for the Social Sciences SPS®. The descriptive characteristics of the study population are described in the following tables. 
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The age distribution by group is broken down in Table 1 .  Three groups were utilized: Group A, Group B, and Group C. Group A received 0.05mg/kg of atracurium, Group B received 1 .5mg/kg of lidocaine, and Group C received both 0.05mg/kg of atracurium, and 1 . 5mg/kg of lidocaine . Twelve subjects were female, and the remaining two subjects were male. The ASA physical status of subjects was as follows: Eight ASA class I subjects, and six ASA class II subjects. Table 2 shows the distribu�ion of ASA and smoking status. The OAFS is a four-point ordinal tool that allows for ranking of observed muscular fasciculations on a scale of 0-3 based on their occurrence and severity. Table 1 Age of Subjects by Study Groups Group Mean age SD Minim�m age Maximum. Age · Atracurium 40.8 5 .4 32 46 Lidocaine 26.5 3 .41 22 30 Lidocaine and 3 1 .2 7.08 2 1  41  Atracurium Population 33.2 --- 2 1  46 39 
Table 2 ASA Status and Smoking Status by Study Group Group ASA I ASA II Smokers Nonsmoker Atracurium N=3 N=2 N=0 N=S Lidocaine 
N=4 N=0 N=0 N=4 Lidocaine and 
N=l N=4 N=3 N=2 Atracurium N=Ntimber of Subjects within each category After calculating the severity and occurrence of fasciculation, it was interesting to note that no subjects in any group scored greater than 1 on the 4-point OAFS. This significance of this finding will be discussed later in the Chapter V. The incidence of smoking and its relevance, if any, to the current study was also examined. Only 3 subjects out of 14 were smokers. Of the 14 subjects in this pilot study analyzed, none of subjects in the lidocaine group smoked, 60% of subjects in the lidocaine/atracurium group smoked, and no subjects in the atracurium were smokers. When considered as a single cohort, smokers were found to exhibit fasciculations 67% of the time, while non-smokers were found exhibit signs of fasciculation 36% of the time. Keep in mind that all three groups had small populations, and that only the combination 
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group had subjects that smoked. It would be interesting to see this break down in a study with larger groups. The mean fasciculation scores are listed in Table 3. The comparison of the mean scores (Table 3) of the three study groups regarding the occurrence of fasciculation was calculated using a nonparametric one-way ANOV A, see Table 4. This test yielded no statistical significance regarding the incidence and severity of fasciculations, P-value of 0.627. In an Analysis of Variance (ANOVA), the measurement of distance between individual distributions is expressed as an F value. An F of one would indicate that the null hypothesis is true for this study, an F value of 0.486 was determined. The null hypothesis for this study stated that there would be no difference in the observed severity Table 3 Fasciculation: Study Group Means Mean Standard N-Deviation value Atrqcurium 0.60 0.54 5 Lidocaine 0.25 0.50 4 Combination 0.40 0.55 5 
4 1  
Table 4 ANOV A: Comparison of Study Group Means Sum of squares Df Between Groups .279 2 Within Groups 3 . 150 1 1  Total 3 .429 1 3  * = Significant difference at the a. = 0.05 level NS = Not Significant Df=degrees of freedom Mean square F Significance 0. 1 39 0.486 NS-0.627 0.286 of fasciculations in surgical patients who receive SCh who are pretreated with one of three pharmacological regimens consisting of either lidocaine, atracurium, or lidocaine and atracurium in combination? In spite of an F of 0.486, all groups exhibited to be effective in decreasing fasciculations, with no group having a score higher then one on the OAFS. The significance of this statistical finding was that when viewing all subjects together, they appeared to be more homogeneous than when they were viewed in groups. The F value for this study was a typical indicator of a highly non-significant result. Since no statistical significance was found, no post-hoc analysis was performed. In addition to the one-way ANOV A, a cross tabulation (Table 5), was run comparing the occurrence of fasciculation among all 3 study groups. Forty percent of subjects in the atracurium group exhibited no signs of fasciculation, which equated to a score of zero on 
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Table 5 
Cross Tabulation of the Occurrence of Fasciculation Within Groups Fasciculation Group Count Total 0.00 1 .00 2 3 5 % within group 40.0% 60.0% 100.0% Atracurium % within Fasciculation 25.0% 50.0% 35 .7% % of Total 14.3% 21 .4% 35 .7% 3 1 4 % within group 75.0% 25.0% 100.0% Lidocaine % within Fasciculation 37.5% 16.7% 28.6% % of Total 2 1 .4% 7. 1% 28 .6% 3 2 5 Atracurium % within group 60.0% 40.0% 100.0% and % within Fasciculation 37.5% 33.3% 35.7% Lidocaine % of Total 21 .4% 14.3% 35 .7% 8 6 14 % within group 57. 1% 42.9% 100.0% Total % within Fasciculation 100.0% 100.0% 100.0% % of Total 57. 1% 42.9% 100.0% 43 
the OAFS. Seventy-five percent of subjects assigned to the lidocaine group scored a zero on the OAFS. The lidocaine/atracurium group had 60% of subjects score zero. As previously mentioned, these data supported the fact that no statistical significance existed when all three groups were compared. Since such a small population was used for this pilot study (N=l4), it was an expected finding that statistical tests would not identify any statistical significance between lidocaine, atracurium, or lidocaine and atracurium in combination, and as expected, none was found (P=. 627). However, when looking at the three groups individually, there were differences between groups regarding the occurrence of fasciculations. This author feels that the differences found among the groups establishes clinical significance and warrants a larger-full scale study to further investigate the validity of the different findings among treatment with lidocaine, atracurium, or lidocaine and atracurium in combination. In addition there were no subjects in any group to score greater then 1 on the OAFS. This too is clinically significant if indeed it was the treatment drugs that kept all OAFS scores at one. All investigations that used the OAFS and looked at NDMRs and lidocaine showed some scores greater then 1 .  Perhaps the group size played a role in this pilot study' s findings. Following the evaluation of the data with the (one-way ANOV A), a Kruskal­Wallis test, (Table 6), was utilized to compare the ranks of fasciculation score among the group and to verify the results computed by the ANOV A. Among all subjects that fasciculated, the maximum observed OAFS score was one. Therefore, among all groups, no subjects scored greater than one on the OAFS, which indicates that all treatments may 
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have been effective in attenuating the severity of fasciculations. This test calculated a P­value of 0.590, which also indicated statistical insignificance. 
Summary The answers to the research question was as follows: All pretreatment results in no subject scoring greater then a score of one on the OAFS. Clinically, 1.5mg/kg of lidocaine appeared to be most effective at preventing the occurrence of fasciculations 75% of the time. Forty percent of subjects receiving 0.05mg/kg of atracurium did not fasciculate. When lidocaine and atracurium were given in combination sixty percent of subjects failed to fasciculate. This study found that it would be feasible to perform a full-scale study comparing nondepolarizing blocking agents and lidocaine with their relation to the attenuation of fasciculation when SCh is utilized as a component of a general anesthetic. There are enough subjects available to perform a larger study, if time is not a consideration. Because of the low risks associated with this type of study, subjects are willing to participate, only one subject failed to give informed consent when approached. All three groups were effective at reducing the severity of fasciculations equally, with no group having any subjects score higher then 1 on the OAFS. Lidocaine followed by the combination of atracurium and lidocaine, and atracurium by itself showed to be an effective pretreatment for preventing fasciculations. Smokers exhibited fasciculations more often then nonsmokers when given lidocaine alone and when combined with atracurium. No smokers were assigned to the atracurium group for comparison. 
46 
CHAPTER V Conclusions and Discussion The conclusions and implications of the findings are discussed in this chapter. Comparison ofstudy results with current literature and recommendations for future research are al�o addressed. The purpose was to examine and compare the efficacy of pretreatment with lidocaine, atracurium, or lidocaine and atracurium in combination as they relate to the incidence and severity of fasciculation in subjects receiving succinylcholine. A second purpose was to determine the feasibility of conducting a full­study to compare the differential effects of pretreatment with lidocaine, atracurium, or lidocaine and atracurium in combination as they relate to the incidence and severity of fasciculation in subjects receiving succinylcholine. A third purpose was to identify correlations between demographic data and fasciculation in subjects who received lidocaine, atracurium, or lidocaine and atracurium in combination as they relate to the incidence and severity of fasciculation in subjects receiving succinylcholine. Currently, there is much research available by a multitude of authors who have studied these classes of drugs. However, the current findings and science regarding their uses as defasciculating agents preceding the administration of a depolarizing muscle relaxant drug fail to identify a best practices regimen to attenuate· succinylcholine­associated fasciculations. Following IRB approval and randomization of treatment drugs by the operating room pharmacy, subjects were identified as described in Chapter III. Identification of potential subjects meeting study criteria initiated chart reviews to confirm appropriateness for inclusion in the study. Those individuals determined to be acceptable 
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for inclusion were approached to elicit their interest in participation. If interested, 
informed consent was obtained; the pharmacy was provided the subject's name, weight, 
BMI, and height for appropriate calculation and preparation of study drugs for dispensing 
in a randomized manner per standardized study protocol. 
Discussion 
The principle purpose of this pilot study was to determine the feasibility of 
conducting a full-study to compare the differential effects of pretreatment with lidocaine, 
atracurium, or lidocaine and atracurium in combination as they relate to the incidence and 
severity of fasciculation in subjects receiving SCh. This study followed the current 
design that had been used by previous investigators. This pilot study was a prospective, 
double blinded, randomized study of 15 ASA Physical Status I and II class subjects who 
underwent general endotracheal anesthesia for laparoscopic surgery. Subjects were 
randomly assigned to one of three groups: one group being administered atracurium 
alone, a second group of subjects receiving lidocaine alone, and a third group who 
received both atracurium and lidocaine. 
Data analysis was conducted utilizing SPSS statistical software. Subjects were 
observed for evidence of fasciculation and severity scored based on the OAFS. The 
mean scores of each group was compared utilizing a one-way ANOV A to detect 
interaction effects between variables, without statistical significance being found. 
It was determined that the study design was appropriate and that it could be 
easily conducted with a larger population, future study of this topic could be readily 
undertaken by utilizing a similar research design. It was also believed that the results of 
this pilot study justifies a larger scale investigation, which would focus on the 
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administration ofNDMR and lidocaine to attenuate fasciculations associated with the use of succinylcholine. This belief is based on the relative ease of subject access and the considerable degree ofclinical significance found as a result of the conduction of the study. The secondary purpose of this pilot study was to examine and compare the efficacy of pretreatment with lidocaine, atracurium, or lidocaine and atracurium in combination as they relate to the incidence and severity of fasciculation in subjects receiving succinylcholine. With this in mind, the analysis of the data sets examining the results of this pilot study investigation demonstrated that, among the subjects treated with l .5mg/kg of lidocaine alone (n=4), 75% of subjects showed no signs of fasciculation. When looking at the subjects that received 0.05mg/kg of atracurium alone (n=5), 40% did not fasciculate. Sixty percent of subjects (n=5) that received both l . 5mg/kg of lidocaine, and 0.05mg/kg of atracurium did not fasciculate. When comparing these results with those found in the extant literature, the results varied as anticipated with a small population. Martin et al ( 1998) found that 65 % of subjects failed to fasciculate when smaller doses of atracurium (0.02mg/kg vs. 0.05mg/kg were used over a shorter time interval (3-min. vs. 5-min). At the same dose of atracurium utilized in this pilot study, 0.05mg/kg, Hochhalter (1 996) found that among 26 subjects receiving atracurium 73% showed no fasciculations, and among 20 subjects receiving 0.05mg/kg of atracurium, Raman & San, (1997) found 60% of subjects failed to exhibit signs of fasciculations. This study' found 40% of subjects in the atracurium group exhibited signs of fasciculations. This is close to the findings of Raman and San ( 1997). It is postulated that had more subjects been studied, as in a full study, the results would 
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have demonstrated that greater than 40% of subjects receiving lidocaine may not have fasciculated. The investigation performed by Raman & San in 1997 was very similar to this author's study. Even though they used the same drugs, same drug doses and groups, they did, however, have a larger population. Raman & San found 60% of subjects receiving atracurium alone and as follows for lidocaine and the combination group. Twenty subjects received l .5mg/kg of lidocaine alone and only 15% did not fasciculate, and 70% of their combination group did not exhibit signs of fasciculation. The findings �f this pilot study showed lidocaine to be much more effective at preventing fasciculation then did that of Raman and San, (75% vs. 15%) and although this is not a statistically significant finding to be generalized beyond these fifteen subjects, it is of potential clinical significance, and reinforces the importance for further investigation in this area of the science. A third purpose of this study was to identify correlations between demographic data and fasciculation in subjects who received lidocaine, atracurium, or lidocaine and atracurium in combination as they relate to the incidence and severity of fasciculation in subjects receiving succinylcholine. To that end, it was interesting to note the influence of smoking on fasciculation. Results would appear to suggest that this subpopulation of subjects tended to fasciculate more often than non-smokers, even when pretreated to attenuate fasciculations that occur after succinylcholine administration. Because this study subpopulation was so small, and the distribution of smokers among the groups was uneven, it is not possible to make any generalizations or suggest that smokers may fasciculate more than nonsmokers. This observation, however, makes for interesting 50 
consideration, and the possibility of correlation should be explored further in future studies. 
Confounding Variables There were many factors that contributed to the completion of this study. The willingness of the pharmacy, operating room staff, anesthesia providers, and surgeons to allow time for subject consent, preparation of study drugs, and administration of the study protocol all played a vital role and helped facilitate the investigation. These individuals took time out of their normal routine to allow for informed consent to be obtained, study drugs to be properly prepared for administration, and time for individual anesthesia providers to explain the study protocol to any other anesthesia providers recruited to assist with data collection. Although an abundance of laproscopic procedures were performed at this investigation site, many potential subjects had to be excluded from inclusion in the study because their BMI was too high, frequently being greater then 30. Since all drug dosages were based on subject weight, changing the inclusion criteria to allow the inclusion of patients with a higher BMI should be considered in future studies. While there were many people and events that aided the completion of this study, there were a few unforesee? matters that hampered the maximally efficient completion of this study. Due to the many responsibilities of the operating room pharmacist and the ever-increasing pressure for rapid tum over between surgical cases, there were times when, following the securing of informed consent from a qualified study subject, there simply was not enough time to get the required information to the pharmacy, contact the pharmacist and have the drugs drawn up in time for the subject 's case. 
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The scarcity of extra personnel in today's busy surgical environments means that everyone is usually working at maximum efficiency and may not have the resources of time and labor to facilitate a research study. Thus, this author suggests allowing a longer time frame for data collection and reinforcing the importance of the chosen observer being present for every subject. If the person will not be available, this needs to be accepted as a limitation up front. The anesthesia department's researcher was chosen to be the single fasciculation observer. The independent researcher, however, has many responsibilities and so was not always available when subject observation was needed. Because this study was a pilot study with fifteen subjects, the findings were not expected to be generalizable to larger population. The intention of this investigation _was to determine the feasibility of a larger future study regarding the use of lidocaine alone,·· atracurium alone and lidocaine in combination with atracurium and their role in preventing fasciculations. While impossible to eliminate all variables in human subjects research, the influence of the identified limitations and confounding variables could have been greatly reduced with a larger sample sizes. In addition, there were some unforeseen aspects of this investigation that were problematic for the researchers. Because of the small sample size, unequal division of subjects among study group occurred . . Of the fifteen subjects chosen one had to be excluded, leaving the lidocaine group with one subject less than the others. Because only fifteen subjects were randomized by the operating room pharmacy, finding and using a sixteenth subject would have upset the randomization. Excluding subjects from analysis is a potential problem and there are few things that could have been done other than having a larger population from the beginning. However, since this was a pilot study and statistical significance was not a 
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goal or an expected finding of this research study, this situation did not prove to be problematic. When examining the unequal gender distribution that occurred in this pilot study, it is important to remember that at this facility it appears that more women tend to undergo laproscopic surgeries than do men. The population size of 15  left far fewer men than women for analysis. This situation could be overcome in future studies with a larger population or by using a type of surgery where there would be a more equal gender distribution, such as cystoscopies for stent placement. When looking at smokers, the distribution was also skewed among the groups because of the small population and this must be accepted as a limitation. The operating room pharmacist was not always available to prepare the study drugs. This is beyond the author's control because the pharmacists have other responsibilities and, since this was not a funded study, they could not be expected to put their duties aside whenever a subject was enrolled. Multiple observers had to be utilized to judge fasciculation with the OAFS. Whenever multiple observers are utilized, there is always the potential for variability among observation, even when all observers were explained the OAFS. This, unfortunately, has a large effect ·on the validity of this study' s results. In the future, investigators must have a dedicated observer or accept the consequence of possibly invalid findings. No control group was utilized because it is known that there is an association between fasciculations and the administration of succinylcholine. However there may have been a statistical significance between the treatment groups and a control group that did not receive a defasciculator. Also a control group was not utilized because of the 
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association ofmyalgias with fasciculation and subjects may have been less willing to participate if a control group was utilized. It is postulated that a control group should be utilized in future studies for comparison and to determine if statistical significance between treatment groups and a control may exist. Because different medications have different onset times, a five-minute interval was chosen to ensure onset of treatment medications. When inducing a general anesthetic, however, five minutes is a long time to w�it. This leaves the chance that anesthesia providers who participated in this study may not have truly waited the five­minutes. This possibility exists and should be considered. The importance of following study protocols should be emphasized for all future researchers. 
Findings · The most surprising and completely unexpected finding of this pilot study was that 75% of subjects receiving lidocaine did not fasciculate thus, lidocaine administered alone was demonstrated to be the most effective agent for preventing fasciculations when compared to atracurium alone, ( 40% ), and to atracurium in combination with lidocaine, (60%). Melnick, Chalasani, Nonita, Uy, Phitayakom, Mallett, and Rudy (1 987) found lidocaine to be no more effective then normal saline at reducing fasciculations. All the current literature reviewed in preparation for this thesis showed lidocaine to be the least effective for attenuating fasciculations following succinylcholine administration when compared to atracurium and other nondepoloraizing muscle relaxants such as d­tubocurarine. The current literature looking at lidocaine alone is minimal because the existing studies show NDMRs alone and in combination with lidocaine to be more effective and this appears to be where the current focus is. Whether or not the results of 
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this study will be supported with data from future investigations will have to be determined in subsequent studies. This factor, in complete isolation, provides support for continuing the collection of data on this subject and to seek to establish statistical significance. To do so would be to offer the profession a tremendous amount of knowledge capable of altering practice for the betterment of patients. Lidocaine is economically far superior to all commercially available muscle relaxants in use at this time for the purpose of preventing fasciculations in patients receiving depolarizing neuromuscular blockade as a component of their general anesthetic. The use of lidocaine for defasciculation represents the expenditure of pennies for each patient in contrast to dollars to utilize a nondepolarizing agent. In addition, the large margin of safety and dramatically lower potential for negative outcome when lidocaine is utilized, in comparison to any nondepolarizing neuromuscular blocking agent, further supports the need to validate these clinical significant findings with larger subject sample sizes. Sixty percent of the subjects in this pilot study who received lidocaine along with atracurium did not fasciculate (n=5). This author expected that this finding would have been higher. Melnick, Chalasani, Nonita, Uy, Phitayakom, Mallett, and Rudy ( 1 987) found the combination of dTc and lidocaine to be superior to both dTc or lidocaine whe� utilized individually for attenuating fasciculations. When comparing the results of Raman and San ( 1997) and the results of this author' s pilot study, in regard to the similarity of the combination of lidocaine with atracurium, the observed results were similar. Both studies used l .5mg/kg of lidocaine and 0.05mg/kg of atracurium. Seventy percent of the subjects in Raman and San's study who received both did not fasciculate 
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and 60% of the subjects in this pilot study did not fasciculate. This study' s findings were similar and show that this finding has some validity and should be further investigated. 
Recommendations for Future Study/Investigation Although the current science regarding the relationship between nondepoloraizing muscle relaxants and the local anesthetics is large and many aspects have been studied, no specific drug or combination of drugs is spelled out to be the best for the prevention of fasciculations. Every study is going to have its limitations. It is impossible to have a perfect study design. Unexpected events are going to occur and they may result in accidental findings, or incorrect findings that, if followed, can result in injury. It is important for all researchers to relay information they found, problems they have incurred, and to offer suggestions to other researchers. This is important because it helps future studies to be designed and carried out with minimal limitations, and problems. It also allows practitioners to make.more informed decisions regarding their practice. By taking into consideration the mistakes and problems others have incurred, more generalized studies can be designed and implemented. Recommendations for future studies are as follows, to undertake: 1. Larger studies looking at any relationship between the occurrence of fasciculations and smoking. 2. Larger studies looking at the role gender may or may not play on fasciculations. 3. Larger studies comparing lidocaine, atracurium, and their combination and their ability to attenuate fasciculations. 4. Studies including a control group as well as the treatment groups. 56 
5 .  Studies having one observer for _all subjects. 
Conclusions In summary, this pilot study was conducted to : 1 ). Establish the feasibility of performing a full-scale study to investigate nondepolarizing neuromuscular blocking agents and their relation to the attenuation of fasciculation when SCh is utilized as a component of a general anesthetic. 2). Appraise the difference in observed fascicul':1,tion when lidocaine alone, atracurium alone, or lidocaine and atracurium in combination are administered as a defasciculating agent prior to SCh. 3). Identify and uncover statistical trends that occurred within the study population that may hold clinical significance without statistical significance, due to the low number of subjects ·studied. The results were not statistically significant or able to be generalized to larger populations. However data analysis demonstrated potential clinical significance, as evidenced by low OAFS scores and a greater number of subjects, than not failing to fasciculate to any measurable or observable degree. This finding warrants further investigation with larger populations. The combination of l .5mg/kg of lidocaine in combination with 0.05mg/kg of atracurium was found to have similar effects preve1:1ting fasciculation as other studies/authors have found. No subject that was observed to fasciculate in any of the three groups received a OAFS score greater then one. Signs of fasciculation could have been missed by any of the many observers leading to inaccurate . · fasciculation recording. It seems reasonable to assume that the variable of smoking may have played a role in fasciculation. However, generalizations cannot be made from a 
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Observers Assessment of Fasciculation Scale (OAFS) [0] No fasciculations witnessed [ 1] Mild, fine fasciculations of the eyes, face, neck or fingers without limb movement [2] Moderate fasciculations of greater intensity than mild that occurred at more than two sites or that produced limb movement [3] Severe vigorous, sustained and widespread fasciculations possibly requiring forceful retention. 
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Appendix B 
ASA Physical Status Classification http://www.asahq.org/clinicaVphysicalstatus.htm Class 1- A normal healthy patient Class 2-A patient with mild systemic disease Class 3 -A patient with severe systemic disease Class 4-A patient with severe systemic disease that is a constant threat to life Class 5-A moribund patient who is not expected to survive without the operation Class 6- A declared brain-dead patient whose organs are being removed for donor purposes Class E- If the procedure is an emergency, the physical status is followed by an "E" 
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Appendix C 
Standards for Basic Intraoperative Monitoring Note: Within these standards, "Anesthesia" is defined as all types of anesthesia care unless otherwise specified by the text. (Approved by House of Delegates on October 2 1 ,  1 986 and last amended on October 21 ,  1 9981)  http://www.asahq.org/publicationsandservices/ standards/02.html These standards apply to all anesthesia care although, in emergency circumstances, appropriate life support measures take precedence. These standards may be exceeded at any time based on the judgment of the responsible anesthesiologist. They are intended to encourage quality patient care, but observing them cannot guarantee any specific patient outcome. They are subject to revision from time to time, as warranted by the evolution of technology and practice. They apply to all general anesthetics, regional anesthetics and monitored anesthesia care. This set of standards addresses only the issue of basic anesthetic monitoring, which is one component of anesthesia care. In certain rare or unusual circumstances, I ) some of these methods of monitoring may be clinically impractical, and 2) appropriate use of the described monitoring methods may fail to detect untoward clinical developments. Brief interruptions of continual# monitoring may be unavoidable. Under extenuating circumstances, the responsible anesthesiologist may waive the requirements marked with an asterisk (*); it is recommended that when this is done, it should be so stated (including the reasons) in a note in the patient's medical record. These standards are not intended for application to the care of the obstetrical patient in labor or in the conduct of pain management. 
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STANDARD I Qualified anesthesia personnel shall be present in the room throughout the conduct of all general anesthetics, regional anesthetics and monitored anesthesia care. OBJECTIVE Because of the rapid changes in patient status during anesthesia, qualified anesthesia personnel shall be continuously present to monitor the patient and provide anesthesia care. In the event there is a direct known hazard, e.g., radiation, to the anesthesia personnel, which might require intermittent remote observation of the patient, some provision for monitoring the patient must be made. In the event tha� an emergency requires the temporary absence of the person primarily responsible for the anesthetic, the best judgment of the anesthesiologist will be exercised in comparing the emergency with the anesthetized patient's condition and in the selection of the person left responsible for the anesthetic during the temporary absence. STANDARD II During all anesthetics, the patient's oxygenation, ventilation, circulation and temperature shall be continually evaluated. OXYGENATION OBJECTIVE To ensure adequate oxygen concentration in the inspired gas and the blood during all anesthetics. 
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METHODS Inspired gas: During every administration of general anesthesia using an anesthesia machine, the concentration of oxygen in the patient breathing system shall be measured by an oxygen analyzer with a low oxygen concentration limit alann in use.* Blood <>.?C:ygenation: During all anesthetics, a quantitative method of assessing oxygenation s�ch as pulse-oximetry shall be employed.* Adequate illumination and exposure of the patient are necessary to assess color.* VENTILATION OBJECTIVE To ensure adequate ventilation of the patient during all anesthetics. METHODS Every patient receiving general anesthesia shall have the adequacy of ventilation continually evaluated. Qualitative clinical signs such as chest excursion, observation of the reservoir breathing bag and auscultation of breath sounds are useful. Continual monitoring for the presence of expired carbon dioxide shall be performed unless invalidated by the nature of the patient, procedure or equipment. Quantitative monitoring of the volume of expired gas is strongly encouraged.* When.an endotracheal tube or laryngeal mask is inserted, its correct positioning must be verified by clinical assessment and by identification of carbon dioxide in the expired gas. Continual end-tidal carbon dioxide analysis, in use from the time of endotracheal tube/laryngeal mask placement, until extubation/removal or initiating transfer to a postoperative care location, shall be performed using a quantitative method such as capnography, capnometry or mass spectroscopy.* 
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When ventilation is controlled by a mechanical ventilator, there shall be in continuous use a device that is capable of detecting disconnection of components of the breathing system. The device must give an audible signal when its alarm threshold is exceeded. During regional anesthesia and monitored anesthesia care, the adequacy of ventilation shall be evaluated, at least, by continual observation of qualitative clinical signs. CIRCULATION OBJECTIVE To ensure the adequacy of the patient's circulatory function during all anesthetics. METHODS Every patient receiving anesthesia shall have the electrocardiogram continuously displayed from the beginning of anesthesia until preparing to leave the anesthetizing location.* Every patient receiving anesthesia shall have arterial blood pressure and heart rate determined and evaluated at least every five minutes.* Every patient receiving general anesthesia shall have, in addition to the above, circulatory function continually evaluated by at least one of the following: palpation of a pulse, auscultation of heart sounds, monitoring of a tracing of intra-arterial pressure, ultrasound peripheral pulse monitoring, or pulse plethysmography or oximetry. BODY TEMPERATURE OBJECTIVE To aid in the maintenance of appropriate body temperature during all anesthetics. 76 
METHODS Every patient receiving anesthesia shall have temperature monitored when clinically significant changes in body temperature are intended, anticipated or suspected. #Note that "continual" is defined as "repeated regularly and frequently in steady rapid succession" whereas "continuous" means "prolonged without any interruption at any time." 
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Appendix D 
Acceptable Hemodynamic Monitoring Parameters Heart rate: +/- 20% of baseline Blood Pressure: +/- 20% of baseline Oxygen S�turation: 95% or above Temperature: 35.6 C (96.0) - 37.8 C (100.0 F) 79 
Appendix E 
Extubation Criteria 
( 1 )  Train of four i s  4/ 4 without fade, and a positive sustained tetanus 
(2) Spontaneous respirations of >8, with a tidal volume of>250 
(3) Negative Inspiratory pressure (NIP) of -10 
( 4) Eye opening to voice, or purposeful movement 
8 1  
Appendix F 
Demographic Data Sheet and Master Subject List Name Phone # Subject # Physical Status- I or II Wt. in kg Ht. in inches Gender Smoking hx/# of yrs Pre-op NSAID NARC Observers Assessment of Fasciculation Scale 




A Comparison of the Differential Effects of Atracurium and/or Lidocaine on 
Succinylcholine-induced Fasciculation and severity of Postoperative Myalgia 
Investigators 
Jack Chavez M.D., Fred Schrimpe, BSN, SRNA, Tonya Campbell, BSN, SRNA Informed Consent The study in which you are asked to participate has the goal of reducing muscle twitching and muscular soreness after surgery, which can occur with succinylcholine administration. This is a topic that is :frequently studied. Many scientists feel that the muscle soreness some people experience after surgery is related to the muscle twitching occurring with succinylcholine administration. You are being asked to participate because you are in a group of patients who frequently have muscle soreness after surgery, namely, patients receiving succinylcholine for general tracheal anesthesia. Succinylcholine is a muscle relaxant that allows your anesthesia provider to place a breathing tube in your windpipe to protect your airway after you are asleep. This tube allows you to breath the anesthetic gases that will keep you asleep. This is done routinely for general anesthesia and will be required regardless of your participation in this study. You should be unaware of this tube placement and should not remember it. All subjects will be selected from the daily surgical schedule at the University of Tennessee Medical Center. This study will examine two anesthetic medications that are routinely used to prevent muscular twitching and soreness. Neither drug has been proven superior in preventing muscle twitching or muscular soreness. We are asking permission to do two things during this study. First, to record any muscular twitching we may observe, and second, to ask you some simple questions after surgery about whether you are experiencing any muscular soreness. You will be contacted by phone 24, 48, and 72 hours after your surgery by one of the investigators. If your surgeon admits you to the hospital, you will be visited in your room by one of the investigators. The medications used will consist of a muscle relaxant (atracurium), or local anesthetic/numbing (lidocaine) medication. Some patients may receive both medications. These medications will be administered in a double blind method. This means that neither you nor the anesthesia provider will know which drug was given until the conclusion of the study. The doses of the medicines, however, will be carefully and safely prepared for you under the supervision of a licensed pharmacist. You will receive standard and acceptable doses of all medications, just as you would if you chose not participate in this 
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study. They will look the same, and no one except the pharmacist will know what you received until all the patients have been studied. FS 03/03 Patient Initials Date 1 of 5 --
A Comparison of the Differential Effects of Atracurium and/or Lidocaine on 
Succinylcholine-induced Fasciculation and severity of Postoperative Myalgia 
Investigators 
Jack Chavez M.D., Fred Schrimpe, BSN, SRNA, Tonya Campbell, BSN, SRNA You will be assigned a unique number that will be used to identify you and the information we gather. If something were to happen that required the knowledge of what drug you received we would use that number to obtain the necessary information. There may be around 100 patients involved in this study, and it will probably take several months to gather all the information we need. Risks Associated with Participation Since the medications you will receive today are routinely used for anesthetics, there is essentially no increased risk to you associated with your participation in this study. However all medications have side effects and could cause adverse reactions. Although rare, some possible side effects that could occur include nausea, vomiting, sedation, prolonged muscle weakness, high potassium, increased body temperature, and seizures. If you experience the common side effects of pain, nausea, or vomiting after your surgery, standard medications for these conditions will be administered, just as they would be for anyone else. You are not expected to experience any increased discomfort as a result of your participation in this study. All records are kept confidential. As stated earlier you will be assigned a number which will be used as your identifier, rather than using your name. These records will be kept in the Anesthesia Office under lock and key for a period of five years from the conclusion of the study. After five years, they will be destroyed. Benefits to Participants The hope is to gain information from this study that may help patients in the future with their post-surgery recovery. The potential benefits to the subjects may include a more comfortable recovery time and possibly an earlier return to their pre-surgery level of function. All future patients who undergo surgery and receive succinylcholine could potentially benefit from this study. If this study demonstrates that one or the combination of pretreatment medications has superior ability to diminish or prevent 
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muscle twitching and muscular soreness, then future patients may experience less discomfort after surgery. FS 03/03 Patient Initials Date --
A Comparison of Differential Effects of Atracurium and/or Lidocaine on 
Succinylcholine-induced Fasciculation and severity of Postoperative Myalgia 
Investigators 
2 of 5 
Jack Chavez M.D., Fred Schrimpe, BSN, SRNA, Tonya Campbell, BSN, SRNA Alternatives to participation There is no superior drug or treatment to prevent succinylcholine induced muscle twitches or muscular soreness. Confidentiality Although study results may be published, your confidentiality will be maintained. Your name or information identifying you will not be released without written permission unless required by law. Under federal privacy regulations, you have the right to determine who has access to your personal health information ( called "protected health information" or PHI). PHI collected in this study may include your medical history, the results of physical exams, lab tests, x-ray exams, and other diagnostic / treatment procedures, as well as basic demographic information. By signing this consent form, you are authorizing the researchers at the University of Tennessee Medical Center to have access to your PHI collected in this study and to receive your PHI from (Jack Chavez M.D.), and may.the University of Tennessee Medical Center where you have received health care. In addition, your PHI may be shared with other persons involved in the conduct or oversight of this research, including the (FDA) Food and Drug Administration, the University of Tennessee Medical Center, and the University of Tennessee Graduate School of Medicine Institutional Review Board. Your PHI will not be used or disclosed to any other person or entity, except as required by law, or for authorized oversight of this research study by other regulatory agencies, or for other research for which the use and disclosure of your PHI has been approved by the IRB. Your PHI will be used indefinitely. You may cancel this authorization in writing at any time by contacting the Principal Investigator listed on the first page of the consent form. If you cancel the authorization, continued use of your PHI is permitted if it was obtained before the cancellation and its use is necessary in completing the research. However, PHI 
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collected after your cancellation may not be used in the study. If you refuse to provide this authorization, you will not be able to participate in the research study. If you cancel the authorization, then you will be withdrawn from the study. Finally, the federal regulations allow you to obtain access to your PHI collected or used in this study. However, in order to complete the research, your access to this PHI may be temporarily suspended while the research is in progress. When the study is completed, your right of access to this information will be reinstated. FS 3/03 Patient Initials __ Date __ 
A Comparison of the Differential Effects of Atracurium and/or Lidocaine on 
Succinylcholine-induced Fasciculation and severity of Postoperative Myalgia Investigators 3 of 5 
Jack Chavez M.D., Fred Schrimpe, BSN, SRNA, Tonya Campbell, BSN, SRNA Liability You understand that you are not waiving any legal rights or releasing the hospital or its agents from liability for negligence. You understand that in the event of physical injury resulting from research procedures, the University of Tennessee does not have funds budgeted for compensation either from lost wages or for medical treatment. Therefore, the University does not provide reimbursements for such injuries. By signing this form, you indicate that: You have read the description of the above study and have freely volunteered to participate in it. You have had possible side effects and adverse reactions explained to you and have had alternative therapies explained. You have had an opportunity to ask questions of the investigator and have received acceptable answers. You understand you may .withdraw from this study.at any time and will still receive standard treatment for your condition. Payment for Participation There is no payment in any form to study participants. Costs of Participation There are no additional costs to you for participating in this study. Contact/Questions 
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If you have any questions about the nature of this study, or feel that you have had an adverse reaction, please feel free to contact Jack Chavez, MD at (865-544-9220), Tonya Campbell (865-544-9220), or Fred Schrimpe (865-544-9220). If you have any questions about your rights as a research subject, please call the Institutional Review Board at (865-544-978 1 ). Thank you for your consideration. Consent of Subject I have read or have had read to me the description of the research study as outlined above. The investigator or his/her representative has explained the study to me and has answered all of the questions I have at this time. I have been told of the potential risks, discomforts, side effects and adverse reactions as well as the possible benefits (if any) of the study. FS 03/03 Patient Initials Date -- --
A Comparison of the Differential Effects of Atracurium and/or Lidocaine on 
Succinylcholine-induced Fasciculation and severity of Postoperative Myalgia Investigators 4 of 5 
Jack Chavez M.D., Fred Schrimpe, BSN, SRNA, Tonya Campbell, BSN, SRNA I freely volunteer to participate in this study. I understand that I do not have to take part in this study and that my refusal to participate will involve no penalty or loss of rights too which I am entitled. I further understand that I am free to later withdraw my consent and discontinue participation in this study at any time. I understand that refusing to participate or later withdrawing from the study will not adversely affect my subsequent medical care. Signature ______________ Date __ _ Investigator Signature Date __ _ Witness Date __ _ 
FS 03/03 Patient Initials Date -- --
89 
5 of 5 
Appendix H 
Inclusion and Exclusion Criteria 
Inclusion Criteria 6. 18-50 years of age 7. Subjects requiring elective outpatient laproscopic surgery under general endotracheal anesthesia 8. BMI between 18-30 9. Physical Status I or II 10. Ambulatory patients only 
Exclusion Criteria 13. Those patients not meeting the inclusion criteria as detailed. 14. Allergy to study drugs (lidocaine or atracurium). 15. Subjects .with co-existing disease states that could necessitate a diversion from the planned anesthetic. 16. Subjects who are known to be pregnant. 17. Subjects who are non-ambulatory, bed-ridden, or wheelchair bound. 18. Any subject who does not have access to a telephone, thus preventing post-operative follow-up contact. 19. Subjects who receive narcotic reversals. 20. Refusal to participate in the study. 21. Subjects having any condition that would be contraindicated by the administration of any drug or procedure outlined in this study. 22. Subject or family history of Malignant Hyperthermia. 9 1  




Protocol 12. After informed consent is obtained by one of the investigators, the subject will be transported to the operating room and positioned on the operating table appropriately for the surgical procedure to be performed. 13. Standard monitoring will be in utilized (Appendix C). 14. Subject will be pre-oxygenation with 100% inspired oxygen for two minutes or five-vital capacity breathes. 15. The experimental pretreatment drug will be given with fentanyl 1.5 mcg/kg. (This dose of fentanyl is given to blunt stimulation from laryngoscopy and has not been demonstrated to affect myalgias in previous investigations). 16. Five minutes after the administration of the pretreatment drug an appropriate induction dose of propofol (2-2.5 mg/kg IV) will be given for the induction of general anesthesia. 17. After the induction dose of propofol is administered, and the subject loses their lid reflex, 1.5mg/kg of SCh will be administered intravenously. The subject will be observed for evidence of fasciculations. The fasciculation observer will be the same for all subjects, and this individual (who is trained and qualified as a research assistant, but is not one of the researchers) will classify the severity of any witnessed fasciculation based on the 0-3 Observers Assessment of Fasciculation Scale (OAFS), (Appendix A). 
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1 8. After complete muscle relaxation is verified by 0/4 twitches following ulnar nerve stimulation via cutaneous electrodes, tracheal intubation will be performed and endotracheal tube placement will be verified by standard methods. 19. Anesthesia will be maintained with oxygen, and air or nitrous oxide, and by titrating sevoflurane 0.6%-5% to the individuals subject 's homodynamic stability and necessary a surgical level of anesthesia corresponding to the degree of surgical intervention required. The Bispectral Index (BIS) monitor will be utilized as an adjunctive monitor to help assess the patient's level of anesthetic depth. 20. If the subject's blood pressure and heart rate fluctuates (increases or decreases) greater then 20% of their base line levels (Appendix D), then vasodilators, vasopressors, inotropes, or chronotropes will be administered as appropriate for the situation. If the subject fails to respond, they will be eliminated from this study, their data will not be utilized for analysis, and all further appropriate treatment necessary for the situation will be instituted. 21 . The following drugs will be administered as their need arises: narcotics (fentanyl 2- 10  mcg/kg), nondepolarizing muscle relaxants, antiemetics, steroids, antibiotics, vasoactive drugs, and muscle relaxant reversals. These medications are not part of the study protocol, but are routinely employed in the anesthetized patient. (See Appendix H for this study's formulary, doses and adverse effects of drugs). After completion of the surgery, anesthesia will be discontinued. The subject will administered 100% oxygen, and will be extubated when extubation criteria are met (Appendix E). Following extubation, the subject will be taken to the post-anesthesia recovery room. 
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Appendix J 
Internal Review Board Letters of Approval 
THE UNIVERSITY OF TENNESSEE 
May 16, 2003 
IRB #: 641_3 B 
Institutional Review Boarc 
Office of Researcl 
404 Andy Holt T owe1 
Knoxville, T e�essce 3 7996-014( 
865-974-346( 
Fax: 865-974-280: 
Title: A Comparison of the Differ�ntial Effects of Atracurium and/or Lidocaine on 




1924 Alcoa Hwy. 
John Preston. Advisor 
Nursing 
1200 Volunteer Blvd. 
Campus 
- Jack �vez, Co-PI 
Anesthesia 
UTMCK 
1924 Alcoa Hwy. 
Fredrick Schrimpe1 Co-PI 
Anesthesia 
UTMCK 
19�4 Alcoa Hwy. 
At the meeting of the Institutional -Review Board (IRB) held May 15, 2003� the above protocol 
was reviewed and approved. 
. . . 
This approval for a·period ending one year from the da�e of this letter. Please make timely · 
submission of renewal or prompt notification of project termination (see item #3 below): . � 
Responsibilities of the investigator during the conduct of this project include the following: 
1. Prior approval from the :Committee before insti�ting any changes in the project. 
2. ' To retain signed consent forms from subjects for at least three years following 
completion of the project. 
3 .  To submit a·Fonn D .to report changes in the project or to report termination at 12-
month or less intervals. 
· · 
The Committee wishes you every success in your research endeavor. This office will send you a 
renewal notice (Form R) on the anniversary of your approval date. 
Sincerely, 




JHE UNIVERSITY OF TENNESSEE 
GRADUATE SCHOOL OF MEDICINE 
March 20, 2003 
Jack Chavez, MD 
· Department of Anesthesiology 
The University of Tennessee Medical Center 
1 924 Alcoa Highway 
Knoxville, TN 37920 . 
Office of Institutional Review Board FWA 2301 1924 Alcoa Highway · Knoxville, 1N 37920-6999 (865) 544-9781 FAX (865) 544-9275 
RE: IRS #2233 "A Comparison of the Differential Effects of Atracurium and/or 
Lidocaine on Succinylcholine-induced Fasciculation and the Severity of 
Postoperative Myalgi�" . 
Dear Dr. Chavez, 
On March 18, 2003, the University of Tennessee Graduate School of Medicine in 
Knoxville Institutional Review Board reviewed your above referenceo application. The 
Board voted full approval with no abstentions on ttiis protocol including informed 
consent form. Your research application will be reviewed ·in one year. 
The I nstitutional Review Board · is in compliance with the requirements in Part 50; 
56, Subch�pter D. ' Part 312 of the 21 Code of Federal Regulations published January 27, 
1 981 . 
Any alterations in ·the protocol m_ust be . promptJy re·ported to the Institutional 
Review Board. In addition, annual reapproval (February 2004) is required by the IRS, 
and it is your responsibility as the Principal Investigator to initiate the request 'for approval 
regardless of the time the study ha� been approved by the sponsoring agency. 
You have individual responsibility for reporting to the B_oard in the event of adverse 
reactions. 
�-
Sincerely, #lfA-...0 · 
<f---,(r'.-i.--- 3/203 
Joseph E. Fuhr, PhD 
Chainnan 
Institutional Review Board 
JEF: rt 
&ceptional medicine. &ceptional peopk. 
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VITA 
Frederick Christopher Schrimpe was born in East Islip, New York on March 1 3 , 
1 977. He was one of two children of Frederick and Marie Schrimpe. He completed his 
high school education in 1 995 in Knoxville, Tennessee. Mr. Schrimpe graduated with a 
BSN from the University of Tennessee, Knoxville in 1 999. He worked in the 
Neuro/Respiratory Intensive Care Unit of the University of Tennessee Medical Center­
Knoxville as a staff nurse until July of 200 1 .  _After working for two and a half years as a 
critical care Registered Nurse, he was accepted into the Master's  program at the 
University of Tennessee, Knoxville. He graduated in December of 2003 with a Master's 
of Science in Nursing, Nurse Anesthesia Concentration. 
Mr. Schrimpe is a member of Sigma Theta Tau International Honor Society of 
Nursing, Gamma Chi Chapter, The TN Association of Nurse Anesthetists, and The 
American Association of Nurse Anesthetists. He will begin is career as a nurse 
anesthetist in Nashville Tennessee. Mr. Schrimpe is considering pursuing doctoral 
studies following a post-master's hiatus. 
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